IRIX - IRIDEX Corporation
IRIDEX Corporation Logo

IRIX - IRIDEX Corporation

https://www.iridex.com
Recent News
Powered by Alpha Vantage
Bullish
Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema - Iridex ( NASDAQ:IRIX )
Benzinga • 2 months, 3 weeks ago • score: 0.40
MOUNTAIN VIEW, Calif., June 24, 2025 ( GLOBE NEWSWIRE ) -- Iridex Corporation IRIX, a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, announced today that the first patient has ...
Bullish
Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management
GlobeNewswire • 8 months, 3 weeks ago • score: 0.39
MOUNTAIN VIEW, Calif., Dec. 18, 2024 ( GLOBE NEWSWIRE ) -- Iridex Corporation ( Nasdaq: IRIX ) , a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the publication of a ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic laser systems, delivery devices, and consumable instrumentation to treat vision-threatening eye diseases in ophthalmology. The company is headquartered in Mountain View, California.

52W High
$2.04
52W Low
$0.78
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.65
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-3.61
EV/Revenue (<3 favorable)
0.57
P/S (TTM) (<3 favorable)
0.48
P/B (<3 favorable)
403.21
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
27.64%
Institutions (25–75% balanced)
15.83%
Shares Outstanding
16,992,300
Float
11,286,400
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
49,744,000
Gross Profit (TTM)
19,646,000
EPS (TTM)
-0.32
Profit Margin (>10% good)
-0.11%
Operating Margin (TTM) (higher better)
-0.07%
ROE (TTM) (>15% strong)
-1.06%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.07
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—